Loading clinical trials...
Loading clinical trials...
Phase IIb, Randomised, Double-blind, Placebo-controlled, Multi-centre Trial of Infliximab With Transcriptomic Biomarker and Mechanism Evaluation in Patients With Acute Pancreatitis.
Conditions
Interventions
Infusion of 5 mg/kg Infliximab
Infusion of 10 mg/kg Infliximab
+1 more
Locations
13
United Kingdom
Aberdeen Royal Infirmary
Aberdeen, Aberdeenshire, United Kingdom
University Hospital of Wales
Cardiff, Cardiff, United Kingdom
Royal Cornwall Hospital
Truro, Cornwall, United Kingdom
Royal Devon and Exeter Hospital
Exeter, Devon, United Kingdom
University College London Hospital
London, Greater London, United Kingdom
St Mary's Hospital
London, Greater London, United Kingdom
Start Date
May 1, 2019
Primary Completion Date
July 31, 2026
Completion Date
March 31, 2027
Last Updated
September 4, 2025
NCT06651580
NCT06553651
NCT07395778
NCT07171112
NCT07153809
NCT06899087
Lead Sponsor
University of Liverpool
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions